Cargando…

Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD

BACKGROUND: Neurofeedback (NF) has gained increasing interest among non-pharmacological treatments for Attention Deficit Hyperactivity Disorder (ADHD). NF training aims to enhance self-regulation of brain activities. The goal of the NEWROFEED study is to assess the efficacy of a new personalized NF...

Descripción completa

Detalles Bibliográficos
Autores principales: Bioulac, Stéphanie, Purper-Ouakil, Diane, Ros, Tomas, Blasco-Fontecilla, Hilario, Prats, Marie, Mayaud, Louis, Brandeis, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676623/
https://www.ncbi.nlm.nih.gov/pubmed/31370811
http://dx.doi.org/10.1186/s12888-019-2218-0
_version_ 1783440801145028608
author Bioulac, Stéphanie
Purper-Ouakil, Diane
Ros, Tomas
Blasco-Fontecilla, Hilario
Prats, Marie
Mayaud, Louis
Brandeis, Daniel
author_facet Bioulac, Stéphanie
Purper-Ouakil, Diane
Ros, Tomas
Blasco-Fontecilla, Hilario
Prats, Marie
Mayaud, Louis
Brandeis, Daniel
author_sort Bioulac, Stéphanie
collection PubMed
description BACKGROUND: Neurofeedback (NF) has gained increasing interest among non-pharmacological treatments for Attention Deficit Hyperactivity Disorder (ADHD). NF training aims to enhance self-regulation of brain activities. The goal of the NEWROFEED study is to assess the efficacy of a new personalized NF training device, using two different protocols according to each child’s electroencephalographic pattern, and designed for use at home. This study is a non-inferiority trial comparing NF to methylphenidate. METHODS: The study is a prospective, multicentre, randomized, reference drug-controlled trial. One hundred seventy-nine children with ADHD, aged 7 to 13 years will be recruited in 13 clinical centres from 5 European countries. Subjects will be randomized to two groups: NF group (Neurofeedback Training Group) and MPH group (Methylphenidate group). Outcome measures include clinicians, parents and teachers’ assessments, attention measures and quantitative EEG (qEEG). Patients undergo eight visits over a three-month period: pre-inclusion visit, inclusion visit, 4 “discovery” (NF group) or titration visits (MPH group), an intermediate and a final visit. Patients will be randomized to either the MPH or NF group. Children in the NF group will undergo either an SMR or a Theta/Beta training protocol according to their baselineTheta/Beta Ratio obtained from the qEEG. DISCUSSION: This is the first non-inferiority study between a personalized NF device and pharmacological treatment. Innovative aspects of Mensia Koala™ include the personalization of the training protocol according to initial qEEG characteristics (SMR or Theta/Beta training protocols) and an improved accessibility of NF due to the opportunity to train at home with monitoring by the clinician through a dedicated web portal. TRIAL REGISTRATION: NCT02778360. Date registration (retrospectively registered): 5-12-2016. Registered May 19, 2016
format Online
Article
Text
id pubmed-6676623
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66766232019-08-06 Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD Bioulac, Stéphanie Purper-Ouakil, Diane Ros, Tomas Blasco-Fontecilla, Hilario Prats, Marie Mayaud, Louis Brandeis, Daniel BMC Psychiatry Study Protocol BACKGROUND: Neurofeedback (NF) has gained increasing interest among non-pharmacological treatments for Attention Deficit Hyperactivity Disorder (ADHD). NF training aims to enhance self-regulation of brain activities. The goal of the NEWROFEED study is to assess the efficacy of a new personalized NF training device, using two different protocols according to each child’s electroencephalographic pattern, and designed for use at home. This study is a non-inferiority trial comparing NF to methylphenidate. METHODS: The study is a prospective, multicentre, randomized, reference drug-controlled trial. One hundred seventy-nine children with ADHD, aged 7 to 13 years will be recruited in 13 clinical centres from 5 European countries. Subjects will be randomized to two groups: NF group (Neurofeedback Training Group) and MPH group (Methylphenidate group). Outcome measures include clinicians, parents and teachers’ assessments, attention measures and quantitative EEG (qEEG). Patients undergo eight visits over a three-month period: pre-inclusion visit, inclusion visit, 4 “discovery” (NF group) or titration visits (MPH group), an intermediate and a final visit. Patients will be randomized to either the MPH or NF group. Children in the NF group will undergo either an SMR or a Theta/Beta training protocol according to their baselineTheta/Beta Ratio obtained from the qEEG. DISCUSSION: This is the first non-inferiority study between a personalized NF device and pharmacological treatment. Innovative aspects of Mensia Koala™ include the personalization of the training protocol according to initial qEEG characteristics (SMR or Theta/Beta training protocols) and an improved accessibility of NF due to the opportunity to train at home with monitoring by the clinician through a dedicated web portal. TRIAL REGISTRATION: NCT02778360. Date registration (retrospectively registered): 5-12-2016. Registered May 19, 2016 BioMed Central 2019-08-01 /pmc/articles/PMC6676623/ /pubmed/31370811 http://dx.doi.org/10.1186/s12888-019-2218-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Bioulac, Stéphanie
Purper-Ouakil, Diane
Ros, Tomas
Blasco-Fontecilla, Hilario
Prats, Marie
Mayaud, Louis
Brandeis, Daniel
Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
title Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
title_full Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
title_fullStr Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
title_full_unstemmed Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
title_short Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
title_sort personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with adhd
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676623/
https://www.ncbi.nlm.nih.gov/pubmed/31370811
http://dx.doi.org/10.1186/s12888-019-2218-0
work_keys_str_mv AT bioulacstephanie personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd
AT purperouakildiane personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd
AT rostomas personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd
AT blascofontecillahilario personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd
AT pratsmarie personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd
AT mayaudlouis personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd
AT brandeisdaniel personalizedathomeneurofeedbackcomparedwithlongactingmethylphenidateinaneuropeannoninferiorityrandomizedtrialinchildrenwithadhd